Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152989 | 0.89 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL11035831 | 0.89 | LMNA (1.00) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL928205 | 0.89 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL928226 | 0.89 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL4122238 | 0.89 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL1392640 | 0.89 | LMNA (0.67) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL482059 | 0.89 | CYP1A2 (1.00) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| Hydrochloric Acid SCHEMBL7316011 | 0.88 | LMNA (0.65) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL7689907 | 0.87 | CYP1A2 (0.96) | LMNAKMT2AMEN1CYP1A2PDE3B | |
| SCHEMBL1751891 | 0.87 | CYP1A2 (0.68) | LMNAKMT2AMEN1CYP1A2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0208517-B1 | 6-OXO-PYRIDAZINYL COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-09-12 | — | — | EP | claimed |
| US-4904664-A | INOTROPIC, BRONCHODILATOR, AND VASODILATOR AGENTS; CONGESTIVE HEART FAILURE; CARDIOVASCULAR DISORDERS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-27 | — | — | US | claimed |
| EP-0208517-A2 | 6-Oxo-pyridazinyl compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-01-14 | — | — | EP | claimed |
| US-7820669-B2 | 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20090131448-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7494990-B2 | 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| EP-1716133-B1 | 2-(PIPERIDIN-4-YL)-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070179146-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | ATLANTA PHARMA AG (DE) | 2007-08-02 | — | — | US | disclosed |
| US-7220746-B2 | Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1537100-B1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | disclosed |
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | disclosed |
| WO-2005075456-A1 | 2-(PIPERIDIN-4-YL) -4, 5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075457-A1 | PHTHALAZINONE-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1087769-B1 | USE OF A PYRIDAZINONE DERIVATIVE AS CALCIUM SENSITIZER | ORION CORP (FI) | 2004-03-10 | — | — | EP | disclosed |
| EP-0208517-B1 | 6-OXO-PYRIDAZINYL COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4904664-A | INOTROPIC, BRONCHODILATOR, AND VASODILATOR AGENTS; CONGESTIVE HEART FAILURE; CARDIOVASCULAR DISORDERS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-02-27 | — | — | US | disclosed |
| EP-0208517-A2 | 6-Oxo-pyridazinyl compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131448-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE4D | LMNA 2806/4885KMT2A 2010/4885MEN1 3907/4885 |
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | PDE4A, PDE3A, PDE2A | LMNA 2629/4885KMT2A 2625/4885MEN1 3781/4885 |
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3B | LMNA 3936/4885KMT2A 1684/4885MEN1 3624/4885 |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3A | LMNA 3865/4885KMT2A 1833/4885MEN1 2634/4885 |
| US-20070179146-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE4D | LMNA 2788/4885KMT2A 2124/4885MEN1 3906/4885 |
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE5A | LMNA 2755/4885KMT2A 3218/4885MEN1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.